Cover Image
市場調查報告書

放射線障礙:開發中產品分析

Radiation Injury - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 335688
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
放射線障礙:開發中產品分析 Radiation Injury - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 47 Pages
簡介

放射線障礙是由於曝露在電離放射線造成組織損傷。依曝露部位為全身或是限定部位不同而有所不同。全身受到高輻射劑量照射的情況為急性幅射傷害,身體局部的情況則為局部性放射線障礙。

本報告提供放射線障礙的治療藥的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

放射線障礙概要

治療藥的開發

  • 開發中產品:概要
  • 開發中的治療藥:各企業
  • 調查中的治療藥:各大學/研究機關
  • 開發中的產品:各企業
  • 調查中的產品:各大學/研究機關

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • FirstString Research Inc
  • PharmaIN Corp
  • Synedgen Inc
  • Windtree Therapeutics Inc

藥物簡介

暫停的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9147IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Injury - Pipeline Review, H1 2017, provides an overview of the Radiation Injury (Toxicology) pipeline landscape.

Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure causes local radiation injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Radiation Injury (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Injury (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 8, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiation Injury (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Injury (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiation Injury (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiation Injury (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiation Injury (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Injury (Toxicology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiation Injury (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiation Injury (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Radiation Injury - Overview
    • Radiation Injury - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Radiation Injury - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Radiation Injury - Companies Involved in Therapeutics Development
    • FirstString Research Inc
    • PharmaIN Corp
    • Synedgen Inc
    • Windtree Therapeutics Inc
  • Radiation Injury - Drug Profiles
    • Aerosurf - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-2E2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-2E5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Des-Asp Angiotensin 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DG-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Granexin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSJ-0017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molgramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYGN-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VEDA-1209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Radiation Injury - Dormant Projects
  • Radiation Injury - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Radiation Injury, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Radiation Injury - Pipeline by FirstString Research Inc, H1 2017
  • Radiation Injury - Pipeline by PharmaIN Corp, H1 2017
  • Radiation Injury - Pipeline by Synedgen Inc, H1 2017
  • Radiation Injury - Pipeline by Windtree Therapeutics Inc, H1 2017
  • Radiation Injury - Dormant Projects, H1 2017
  • Radiation Injury - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Radiation Injury, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top